Lupin gets USFDA nod for generic psoriasis treatment solution

The USFDA approval to Lupin's calcipotriene topical solution is for strength of 0.005 per cent (scalp solution), the company said in a statement.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news

Related Links:

AbstractObjectivesTransforming growth factor beta (TGF β) inhibitor Bone Morphogenetic Protein and Activin Membrane‐Bound Inhibitor (BAMBI) has been shown to control CD4+ T lymphocytes differentiation into either tolerogenic regulatory T (Tregs) or pathogenic TH17 cells through the regulation of TGF β and IL‐2 signaling strength. In the present study, we explore the potential beneficial effects of its pharmacological inhibition with new anti‐BAMBI monoclonal antibodies (mAbs) in different skin and joint experimental chronic‐inflammatory/autoimmune diseases.MethodsDevelopment ofsaccharomyces cerevisiae man...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: FULL LENGTH Source Type: research
Authors: Amat-Samaranch V, Puig L Abstract Introduction: Psoriasis vulgaris is a chronic inflammatory skin disease characterized by well-demarcated red and scaly plaques. Most patients have mild disease that is usually controlled with topical treatment. Calcipotriene 0.05% and betamethasone dipropionate 0.064% (Cal/BD) in aerosol foam (Enstilar®) is a novel formulation, which has shown promising results in terms of efficacy and safety.Areas covered: This review evaluates the safety profile of Cal/BD aerosol foam and also the key points regarding to its efficacy. A literature search was performed in PubMed on No...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
We present herein a case of syphilide psoriasiforme, an uncommon but well recognized clinical presentation of secondary syphilis. A 46-year-old HIV-infected female patient was referred to our attention with a presumptive diagnosis of palmoplantar psoriasis. On examination, there were exuberant pinkish-red papules and plaques covered with a thick silvery scale in the palms, flexor surfaces of the wrists, and the medial longitudinal arches of the feet. Serological and histopathological analyses uncovered the diagnosis of syphilis. Clinical remission was obtained after treatment. A detailed review of the literature on syphili...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - Category: Tropical Medicine Authors: Tags: Rev Inst Med Trop Sao Paulo Source Type: research
NEW YORK (Reuters Health)—The ongoing novel coronavirus pandemic has raised concerns about whether biologic therapy could make psoriasis patients more susceptible to SARS-CoV-2, the virus behind COVID-19. Mark Lebwohl, MD, from Icahn School of Medicine at Mount Sinai Hospital in New York and colleagues address this issue in a letter in the Journal of the... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions coronavirus COVID-19 Dermatology Psoriasis skin Source Type: research
Conclusions: Guselkumab was superior to adalimumab for improvement in WPL and associated indirect cost savings, and its use may reduce the economic burden of psoriasis. PMID: 32233940 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Authors: Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman SR, Armstrong A Abstract Objectives: To compare the cost-effectiveness of tildrakizumab with other commonly used biologics and apremilast as the first-line treatment for moderate-to-severe plaque psoriasis from a US health plan's perspective.Methods: A 10-year cost-effectiveness model was developed to compare the incremental cost per extra month with a Psoriasis Area and Severity Index (PASI) 75 response. Patients were assumed to receive one of the treatments evaluated as their first-line treatment at the outset of the analysis. Nonresponders (PASI
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Publication date: Available online 3 April 2020Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Yangang Cheng, Yan Liu, Jinyan Tan, Yanping Sun, Wei Guan, Peng Jiang, Bingyou Yang, Haixue Kuang
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
Conclusion: We report the efficacy and safety of IFX maintained for up to 12 years in psoriasis patients. The long-term use of IFX was associated with a high BMI confirming the critical role of weight-based dosing for this drug. PMID: 32231699 [PubMed]
Source: Dermatology Research and Practice - Category: Dermatology Tags: Dermatol Res Pract Source Type: research
This study examined weight reduction as well as smoking as potential modifiable risk factors for PsA.The British Journal of Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
The chemokine receptor CCR4 has emerged as a skin-homing molecule important for the migration of T cells from the blood to the dermis. From our previous data on psoriasis patients, CCR4+ memory T cells emerged as a putative recirculating population between skin and blood. Here we focused our attention on the expression of CCR4 and skin-tropic molecules in the different stages of memory T cell differentiation. We analyzed the chemokine receptor profile in CD8+ and CD4+ CD45RA−CCR7+ (TCM) and CD45RA−CCR7− (TEM) cells. Subpopulations were further divided on the basis of CD62L expression, and the distribution...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Biotechnology | Pharmaceuticals | Psoriasis